Compare AbbVie Inc (ABBV) vs Trip.com Group Ltd (TCOM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Trip.com Group Ltd — how do they compare? AbbVie Inc trades at $253.78 (market cap $449.91B), while Trip.com Group Ltd trades at $41.38 (market cap $25.65B). The key difference: AbbVie Inc is far larger — about 17.5× Trip.com Group Ltd's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | TCOM | |
|---|---|---|
Market Cap | $449.91B | $25.65B |
Sector | Health | Consumer Cyclical |
52-Week High | $261.07 | $78.96 |
52-Week Low | $184.85 | $39.84 |
Enterprise Value | $513.38B | $18.35B |
Dividend Yield | 2.72% | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
Trip.com Group (TCOM) trades at $40.81, down 0.46% on the day, near its 52-week low. The stock shows bearish technical signals with oversold RSI readings. Fundamentally, TCOM reported Q1 2026 revenue growth of 17% year-over-year but missed EPS estimates, with Q2 revenue guidance of 3%-8% growth disappointing investors. The company maintains strong profitability with a 48.65% net margin and attractive valuation multiples, including a P/E of 6.16. Recent news highlights regulatory scrutiny and a significant stock selloff following earnings.
The outlook for TCOM is mixed. Strong cash flow, dominant market position in Chinese travel, and low valuations support upside potential toward the $56.72 analyst target. However, near-term risks include regulatory investigations, margin pressure from cost growth, and bearish technical trends. Investors should weigh solid fundamentals against heightened sentiment risks and guidance concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →
